Antianginal Efficacy and Safety of Ivabradine Compared with Amlodipine in Patients with Stable Effort Angina Pectoris

@article{Ruyo2012AntianginalEA,
  title={Antianginal Efficacy and Safety of Ivabradine Compared with Amlodipine in Patients with Stable Effort Angina Pectoris},
  author={Witold Rużyłło and Michal Tendera and Ian Ford and Kim Fox},
  journal={Drugs},
  year={2012},
  volume={67},
  pages={393-405}
}
AbstractBackground and objective: Current medical therapies for the symptoms of angina pectoris aim to improve oxygen supply and reduce oxygen demand in the myocardium. Not all patients respond to current antianginal monotherapy, or even combination therapy, and a new class of antianginal drug that complements existing therapies would be useful. This study was undertaken to compare the antianginal and anti-ischaemic effects of the novel heart-rate-lowering agent ivabradine and of the calcium… 
Short-Term Effects of Ivabradine in Patients with Chronic Stable Ischemic Heart Disease
TLDR
The addition of ivabradine to optimal medical therapy in patients with stable coronary artery disease is associated with significant improvement in anginal symptoms and functional capacity.
Clinical Results of If Current Inhibition by Ivabradine
TLDR
The ongoing clinical development programme with the two major morbidity-mortality studies, BEAUTIFUL and SHIfT, has the potential to greatly extend the use of ivabradine in patients with coronary artery disease as well as in those with heart failure.
Efficacy of Ivabradine in Combination with Beta-Blocker Versus Uptitration of Beta-Blocker in Patients with Stable Angina
TLDR
It is suggested that combining ivabradine with low dose bisoprolol in stable angina patients produces additional antianginal and anti-ischemic benefits and improves chronotropic reserve.
Ivabradine in practice
TLDR
Clinical evidence that ivabradine diminishes angina in all types of patients, whatever their age, sex, severity of angina, and revascularization status, history of previous myocardial infarction, peripheral vascular disease, or diabetes is provided.
Ivabradine in Combination with Beta-Blockers in Patients with Chronic Stable Angina After Percutaneous Coronary Intervention
TLDR
Ivabradine reduced the frequency of weekly angina attacks and nitrate consumption, led to an improvement in Canadian Cardiovascular Society class and a substantial improvement in the QoL of stable angina patients.
Effectiveness and Tolerability of Ivabradine with or Without Concomitant Beta-Blocker Therapy in Patients with Chronic Stable Angina in Routine Clinical Practice
TLDR
In this prospective study over a four-month period in clinical practice, ivabradine effectively reduced HR, angina attacks, and nitrate consumption in patients with chronic stable angina pectoris with or without concomitant BB therapy.
Effectiveness of Ivabradine Treatment in Different Subpopulations with Stable Angina in Clinical Practice: A Pooled Analysis of Observational Studies
TLDR
Ivabradine is effective and safe in all subpopulations of angina patients seen in clinical practice, independent of age, comorbidities, and use of beta-blocker.
Treatment of Stable Angina with a New Fixed-Dose Combination of Ivabradine and Metoprolol: Effectiveness and Tolerability in Routine Clinical Practice
TLDR
Treatment with a FDC of ivabradine and metoprolol was associated with reduced HR and angina symptoms, while exercise capacity (CCS score) was improved, which may be mainly mediated by the increased medication adherence of patients observed with use of the FDC formulation.
Role of ivabradine in management of stable angina in patients with different clinical profiles
TLDR
This heart rate-lowering agent might also improve prognosis, reduce hospitalisation rates and improve QOL in angina patients with chronic HF and LVSD, in particular angina subgroups and in patients with stable angina with left ventricular systolic dysfunction.
The Role of Ivabradine in the Management of Angina Pectoris
TLDR
The available data suggest that ivabradine is a well-tolerated and effective anti-anginal agent and it is recommended as a second-line agent for relief of angina in guidelines, however, recent clinical trials of ivABradine have failed to show prognostic benefit and have raised potential concerns about safety.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 33 REFERENCES
Antianginal and Antiischemic Effects of Ivabradine, an If Inhibitor, in Stable Angina: A Randomized, Double-Blind, Multicentered, Placebo-Controlled Trial
TLDR
The results suggest that ivabradine, representing a novel class of antianginal drugs, is effective and safe during 3 months of use; longer-term safety requires additional assessment.
Efficacy of ivabradine, a new selective I(f) inhibitor, compared with atenolol in patients with chronic stable angina.
TLDR
Ivabradine is as effective as atenolol in patients with stable angina in a double-blinded trial and the number of angina attacks was decreased by two-thirds with both ivab radine and atenOLol.
Choosing the Most Appropriate Treatment for Stable Angina
The goals of stable angina pectoris treatment are: (i) symptom relief and increase in angina-free walking time; and (ii) reduction of mortality and adverse outcome. Strategies used for plaque
Anti-Ischemic Effects of Ivabradine, a Selective Heart Rate-Reducing Agent, in Exercise-Induced Myocardial Ischemia in Pigs
TLDR
The effects of ivabradine, a novel heart rate-reducing agent that inhibits the cardiac pacemaker current If, were compared with those of the propranolol, in a model of exercise-induced regional myocardial ischemia in pigs to show equipotent effects in reducing heart rate at rest and limiting tachycardia during exercise.
Proarrhythmic effects of antiarrhythmic drugs.
  • D. Zipes
  • Medicine, Biology
    The American journal of cardiology
  • 1987
Guidelines on the management of stable angina pectoris: executive summary: the task force on the management of stable angina pectoris of the European society of cardiology.
TLDR
The task force has felt it important, in the absence of unequivocal evidence to the contrary, to preserve consistency between guidelines on prevention and angina with regard to targets for institution of therapy for hypertension in the presence of coronary disease.
...
1
2
3
4
...